G. Yogalingam

发表

Identifying therapeutic drug targets for rare and common forms of short stature

Christopher R. Bauer, L. Cardon, W. Clark, 2020, bioRxiv.

Abl Kinases Regulate Autophagy by Promoting the Trafficking and Function of Lysosomal Components*

A. Pendergast, G. Yogalingam, 2008, Journal of Biological Chemistry.

Regulation of mitochondrial processes: a target for heart failure.

S. Palaniyandi, Julio C. B. Ferreira, D. Mochly‐Rosen, 2010, Drug discovery today. Disease mechanisms.

Intermittent enzyme replacement therapy with recombinant human β-galactosidase prevents neuraminidase 1 deficiency

S. Bunting, Britta Handyside, Sherry Bullens, 2020, Journal of Biological Chemistry.

Intracerebroventricular enzyme replacement therapy with β-galactosidase reverses brain pathologies due to GM1 gangliosidosis in mice

S. Bunting, S. Fong, Britta Handyside, 2019, The Journal of Biological Chemistry.

Abl Kinases Are Required for Invadopodia Formation and Chemokine-induced Invasion*

A. Pendergast, G. Yogalingam, Emileigh Greuber, 2010, The Journal of Biological Chemistry.

Characterization of glycan substrates accumulating in GM1 Gangliosidosis

W. Clark, R. Giugliani, J. LeBowitz, 2019, Molecular genetics and metabolism reports.

Mucopolysaccharidosis type IIIB: characterisation and expression of wild-type and mutant recombinant alpha-N-acetylglucosaminidase and relationship with sanfilippo phenotype in an attenuated patient.

J. Hopwood, J. Meehan, G. Yogalingam, 2000, Biochimica et biophysica acta.

Glyceraldehyde-3-phosphate Dehydrogenase (GAPDH) Phosphorylation by Protein Kinase Cδ (PKCδ) Inhibits Mitochondria Elimination by Lysosomal-like Structures following Ischemia and Reoxygenation-induced Injury*

Julio C. B. Ferreira, D. Mochly‐Rosen, G. Yogalingam, 2013, The Journal of Biological Chemistry.

Short-term, high dose enzyme replacement therapy in sialidosis mice.

A. d’Azzo, E. Bonten, G. Yogalingam, 2005, Molecular genetics and metabolism.

Targeting macrophages with baculovirus‐produced lysosomal enzymes: implications for enzyme replacement therapy of the glycoprotein storage disorder galactosialidosis

A. d’Azzo, E. Bonten, G. Yogalingam, 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Differential Uptake of NAGLU-IGF2 and Unmodified NAGLU in Cellular Models of Sanfilippo Syndrome Type B

J. LeBowitz, R. Lawrence, Bryan K. Yip, 2019, Molecular therapy. Methods & clinical development.

Cellular Uptake and Delivery of Myeloperoxidase to Lysosomes Promote Lipofuscin Degradation and Lysosomal Stress in Retinal Cells*

T. Maures, Agnes Rafalko, G. Berguig, 2017, The Journal of Biological Chemistry.

Purification and characterization of recombinant murine sulfamidase.

J. Hopwood, G. Yogalingam, B. Gliddon, 2004, Molecular genetics and metabolism.

Identification and molecular characterization of α‐L‐iduronidase mutations present in mucopolysaccharidosis type I patients undergoing enzyme replacement therapy

D. Brooks, J. Hopwood, P. Clements, 2004 .

Regulation of N-acetylgalactosamine 4-sulfatase expression in retrovirus-transduced feline mucopolysaccharidosis type VI muscle cells.

J. Hopwood, D. Anson, G. Yogalingam, 1999, DNA and cell biology.

Expression and characterization of human recombinant and alpha-N-acetylglucosaminidase.

J. Hopwood, G. Yogalingam, B. Weber, 2001, Protein expression and purification.

Evaluation of fibroblast-mediated gene therapy in a feline model of mucopolysaccharidosis type VI.

J. Hopwood, D. Anson, G. Yogalingam, 1999, Biochimica et biophysica acta.

Feline Mucopolysaccharidosis Type VI

J. Hopwood, T. Litjens, D. Anson, 1996, The Journal of Biological Chemistry.

Neuraminidase 1 is a negative regulator of lysosomal exocytosis.

A. d’Azzo, E. Bonten, G. Yogalingam, 2008, Developmental cell.

Identification of a mutation causing mucopolysaccharidosis type IIIA in New Zealand Huntaway dogs.

J. Hopwood, G. Yogalingam, R. Jolly, 2002, Genomics.

Molecular genetics of mucopolysaccharidosis type IIIA and IIIB: Diagnostic, clinical, and biological implications

J. Hopwood, G. Yogalingam, 2001, Human mutation.

Glycosidase active site mutations in human α-L-iduronidase

B. Henrissat, J. Mornon, D. Brooks, 2001 .

Feline mucopolysaccharidosis type VI: correction of glycosaminoglycan storage in myoblasts by retrovirus-mediated transfer of the feline N-acetylgalactosamine 4-sulfatase gene.

J. Hopwood, J. Bielicki, D. Anson, 1997, DNA and cell biology.

Identifying therapeutic drug targets using bidirectional effect genes

Christopher R. Bauer, L. Cardon, W. Clark, 2021, Nature Communications.

Two mutations within a feline mucopolysaccharidosis type VI colony cause three different clinical phenotypes.

J. Hopwood, G. Yogalingam, V. Muller, 1998, The Journal of clinical investigation.

Expression and distribution of surfactant proteins and lysozyme after prolonged hyperpnea.

I. Doyle, J. Power, G. Yogalingam, 1996, The American journal of physiology.

Chaperone-mediated gene therapy with recombinant AAV-PPCA in a new mouse model of type I sialidosis.

A. d’Azzo, E. Bonten, G. Yogalingam, 2013, Biochimica et biophysica acta.

Identification and characterization of 13 new mutations in mucopolysaccharidosis type I patients.

D. Brooks, R. Giugliani, U. Matte, 2003, Molecular genetics and metabolism.

Identification and molecular characterization of alpha-L-iduronidase mutations present in mucopolysaccharidosis type I patients undergoing enzyme replacement therapy.

D. Brooks, J. Hopwood, P. Clements, 2004, Human mutation.

Clearance of Heparan Sulfate and Attenuation of CNS Pathology by Intracerebroventricular BMN 250 in Sanfilippo Type B Mice

P. Fitzpatrick, S. Bunting, Catherine Vitelli, 2017, Molecular therapy. Methods & clinical development.

Expression and characterization of human recombinant and alpha-N-acetylglucosaminidase.

J. Hopwood, G. Yogalingam, B. Weber, 2001, Protein expression and purification.

BMN 250, a fusion of lysosomal alpha-N-acetylglucosaminidase with IGF2, exhibits different patterns of cellular uptake into critical cell types of Sanfilippo syndrome B disease pathogenesis

J. LeBowitz, R. Lawrence, Bryan K. Yip, 2018, bioRxiv.

Mutational analysis of the carboxy-terminal region of UDP-glucuronosyltransferase 2B1.

P. Mackenzie, R. Meech, G. Yogalingam, 1996, DNA and cell biology.

Mild Feline Mucopolysaccharidosis Type VI

J. Hopwood, D. Anson, G. Yogalingam, 1998, The Journal of Biological Chemistry.

Molecular cloning of feline CD34.

D. Anson, G. Yogalingam, 2003, Veterinary immunology and immunopathology.

Screening for the Mucopolysaccharidosis-IIIA gene in Huntaway dogs

A. Johnstone, R. Jolly, G. Yogalingam, 2002, New Zealand Veterinary Journal.

Expression and Characterization of Wild Type and Mutant Recombinant Human Sulfamidase

J. Hopwood, S. Byers, G. Yogalingam, 1999, The Journal of Biological Chemistry.

Abl Kinases Regulate Autophagy by Promoting the Trafficking and Function of Lysosomal Components*

A. Pendergast, G. Yogalingam, 2008, Journal of Biological Chemistry.

Intermittent enzyme replacement therapy prevents Neu1 deficiency

S. Bunting, Britta Handyside, V. Agrawal, 2020, The Journal of Biological Chemistry.

Intermittent enzyme replacement therapy with recombinant human b -galactosidase prevents neuraminidase 1 deficiency

Britta Handyside, Jon Vincelette, G. Yogalingam, 2020 .